Emergency department implementation of monoclonal antibody infusion for the treatment of coronavirus disease 2019: A template for rapid deployment.
J Am Coll Emerg Physicians Open
; 2(5): e12550, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1427087
ABSTRACT
Monoclonal antibody (mAb) therapy can improve coronavirus disease 2019 outcomes when infused early in select patients. We sought to rapidly create and implement a program for emergency department (ED) mAb infusion to aid care. Using multiple strategies and actions-education, selection criteria, screening tools, rapid testing, compounding, and delivery-we infused 832 ED patients with a mAb. The screening tool identified 94.5% of these patients as potential candidates. Length of stay was nearly identical for patients who tested positive for coronavirus disease 2019 versus those requiring testing. Mild adverse reactions occurred in 2.3% of mAb infusions, and severe reactions occurred in 0.5% of infusions. We highlight a strategic approach for using the ED as a key coronavirus disease 2019 therapeutic site for this intervention and with high utility and low disruption.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
J Am Coll Emerg Physicians Open
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS